Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Synergistic engineering of anti-tumor immunity by synthetic biomaterials

Project description

Engineering the immune system to fight cancer

Despite its initial promise, immunotherapy against cancer has exhibited limited success in the clinic. This indicates the need for synergistic and safer therapies causing fewer immune-related toxicities. The EU-funded ImmunoBioSynth project proposes to design synthetic biomaterials for instructing the immune system to fight cancer. These innovative biomaterials will replace biological drugs and contribute to the remodelling of the tumour microenvironment from a suppressive into a susceptible state. Ultimately, this will lead to more specific treatments that alone or in combination with other regimens can improve the outcome of cancer patients.

Objective

Immunotherapy holds the potential to dramatically improve the curative prognosis of cancer patients. However, despite significant progress, a huge gap remains to be bridged to gain board success in the clinic. A first limiting factor in cancer immunotherapy is the low response rate in large fraction of the patients and an unmet need exists for more efficient - potentially synergistic - immunotherapies that improve upon or complement existing strategies. The second limiting factor is immune-related toxicity that can cause live-threatening situations as well as seriously impair the quality of life of patients. Therefore, there is an urgent need for safer immunotherapies that allow for a more target-specific engineering of the immune system. Strategies to engineer the immune system via a materials chemistry approach, i.e. immuno-engineering, have gathered major attention over the past decade and could complement or replace biologicals, and holds promise to contribute to resolving the current issues faced by the immunotherapy field. I hypothesize that synthetic biomaterials can play an important role in anti-cancer immunotherapy with regard to synergistic, safe, but potent, instruction of innate and adaptive anti-cancer immunity and to revert the tumor microenvironment from an immune-suppressive into an immune-susceptible state. Hereto, the overall scientific objective of this proposal is to fully embrace the potential of immuno-engineering and develop several highly synergistic biomaterials strategies to engineer the immune system to fight cancer. I will develop a series of biomaterials and address a number of fundamental questions with regard to optimal biomaterial design for immuno-engineering. Based on these findings, I will elucidate those therapeutic strategies that lead to synergistic engineering of innate and adaptive immunity in combination with remodeling the tumor microenvironment from an immune-suppressive into an immune-susceptible state.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

ERC-COG - Consolidator Grant

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2018-COG

See all projects funded under this call

Host institution

UNIVERSITEIT GENT
Net EU contribution
€ 2 000 000,00
Address
SINT PIETERSNIEUWSTRAAT 25
9000 Gent
Belgium
Region
Vlaams Gewest Prov. Oost-Vlaanderen Arr. Gent
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 2 000 000,00

Beneficiaries (1)